Indicator 9.9
Licensing Income, 1997-98 to 2007-08
Income from the 25 top-earning inventions accounted for approximately 75 percent of total royalty and fee income.
By the end of fiscal year 2008, UC held equity in 102 companies acquired under licenses and other agreements involving UC technologies.
Click an image to enlarge.
Source: UCOP Office of Technology Transfer Annual Reports. The full reports can be found at http://www.ucop.edu/ott/genresources/annualrpts.html.
Figures are in constant 2007-08 dollars, adjusted for inflation using GDP deflator. Total licensing income for fiscal year 2008 does not include upfront payments and reimbursements of $42.6 million from the settlement of litigation. In fiscal year 2006, the University received a $100 million payment as a partial settlement of a patent infringement suit involving bovine growth hormone patents. In fiscal year 2000, the University received a $200 million payment as settlement for a long-standing infringement suit involving the University's human growth hormone patent. Because of the unique nature and magnitude of these settlements, monies attributable to them are excluded from the Universitywide and San Francisco campus trend data shown here.
San Francisco’s drop in licensing income since 1997-98 is due in part to the expiration of patents covering the Hepatitis B vaccine, Human Growth Hormone and Gene Splicing inventions.
You may view or download a table of the raw data used to generate these charts in CSV files, which can be opened in spreadsheet programs such as Microsoft Excel or OpenOffice.